Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Free Subscription

Articles published in Eur J Cancer

Retrieve available abstracts of 14 articles:
HTML format

Single Articles

    May 2024
  1. BUHRER E, D'Haese D, Daugaard G, de Wit R, et al
    Impact of teratoma on survival probabilities of patients with metastatic non-seminomatous germ cell cancer: Results from the IGCCCG Update Consortium.
    Eur J Cancer. 2024;202:114042.
    PubMed     Abstract available

  2. WAGNER T, Toft BG, Lauritsen J, Bandak M, et al
    Prognostic factors for relapse in patients with clinical stage I testicular non-seminoma: A nationwide, population-based cohort study.
    Eur J Cancer. 2024;202:114025.
    PubMed     Abstract available

    November 2023
  3. TAN X, Wang Y, Wu Z, Zhou Q, et al
    The role of Her-2 in penile squamous cell carcinoma progression and cisplatin chemoresistance and potential for antibody-drug conjugate-based therapy.
    Eur J Cancer. 2023;194:113360.
    PubMed     Abstract available

    January 2023
  4. ANTONELLI L, Ardizzone D, Ravi P, Bagrodia A, et al
    Risk of residual cancer after complete response following first-line chemotherapy in men with metastatic non-seminomatous germ cell tumour and International Germ Cell Cancer Cooperative Group intermediate/poor prognosis: A multi-institutional retrospe
    Eur J Cancer. 2023;182:144-154.
    PubMed     Abstract available

    September 2022
  5. WANG Y, Lian B, Si L, Mao L, et al
    Cumulative incidence and risk factors of brain metastasis for acral and mucosal melanoma patients with stages I-III.
    Eur J Cancer. 2022;175:196-203.
    PubMed     Abstract available

    May 2022
  6. MIFSUD W, Furtwangler R, Vokuhl C, D'Hooghe E, et al
    Treatment of patients with stage I focal anaplastic and diffuse anaplastic Wilms tumour: A report from the SIOP-WT-2001 GPOH and UK-CCLG studies.
    Eur J Cancer. 2022;166:1-7.
    PubMed     Abstract available

    March 2022
  7. ALIFRANGIS C, Sharma A, Chowdhury S, Duncan S, et al
    Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients.
    Eur J Cancer. 2022;164:105-113.
    PubMed     Abstract available

    October 2021
  8. MALUF FC, Schutz FA, Cronemberger EH, Luz MA, et al
    A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).
    Eur J Cancer. 2021;158:63-71.
    PubMed     Abstract available

  9. VOLDERS ELD, Gietema JA, van Beek AP, Emous M, et al
    Bariatric surgery in a testicular cancer survivor: Restoring both metabolic and testosterone status.
    Eur J Cancer. 2021;158:12-14.

    September 2021
  10. HOVEN E, Fagerkvist K, Jahnukainen K, Ljungman L, et al
    Sexual dysfunction in young adult survivors of childhood cancer - A population-based study.
    Eur J Cancer. 2021;154:147-156.
    PubMed     Abstract available

    August 2021
  11. HIESTER A, Fingerhut A, Niegisch G, Siener R, et al
    Late toxicities and recurrences in patients with clinical stage I non-seminomatous germ cell tumours after 1 cycle of adjuvant bleomycin, etoposide and cisplatin versus primary retroperitoneal lymph node dissection - A 13-year follow-up analysis of a
    Eur J Cancer. 2021;155:64-72.
    PubMed     Abstract available

    July 2021
  12. SALZMANN M, Tosev G, Heck M, Schadendorf D, et al
    Male fertility during and after immune checkpoint inhibitor therapy: A cross-sectional pilot study.
    Eur J Cancer. 2021;152:41-48.
    PubMed     Abstract available

    February 2021
  13. ANDERSON RA, Clatot F, Demeestere I, Lambertini M, et al
    Cancer survivorship: Reproductive health outcomes should be included in standard toxicity assessments.
    Eur J Cancer. 2021;144:310-316.
    PubMed     Abstract available

    March 2020
  14. GILBERT A, Drinkwater K, McParland L, Adams R, et al
    UK national cohort of anal cancer treated with intensity-modulated radiotherapy: One-year oncological and patient-reported outcomes.
    Eur J Cancer. 2020;128:7-16.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Andrology is free of charge.